摘要
结核病的发生、发展及转归与患者的抗结核免疫功能密切相关。结核病患者常常存在抗结核免疫功能的异常,对结核病患者应用免疫制剂进行免疫干预,可提高治愈率、降低复发率,但对活动性结核病患者免疫干预的指征、免疫制剂的选择尚未达成一致意见。发表于《中国防痨杂志》2022年第1期的《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》就抗结核免疫辅助治疗提出了具体建议并达成共识。本文主要对共识中结核病患者免疫异常因素、活动性结核病患者免疫辅助治疗概念、应用免疫制剂进行免疫干预的临床应用及存在问题和建议等进一步解读,以供我国结核病临床工作者借鉴和参考。
The occurrence,development and prognosis of tuberculosis(TB)are closely related to anti-TB immune function.TB patients often have anti-TB immune function abnormalities,the immune intervention using immune agents can improve the cure rate and reduced the recurrence rate.However,there is no consensus on the immune intervention and selection of immune agents for active TB.Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis(2021 Edition)published in No.1 of 2022 in Chinese Journal of Antituberculosis proposed specific suggestions and reached consensus on anti-TB immunotherapy.The factors of immune abnormality in TB patients,the concept of immunoadjuvant therapy for active TB,the clinical application of the immune intervention were further interpreted in this paper,to provide the reference of TB clinical workers in China.
作者
安慧茹
吴雪琼
AN Hui-ru;WU Xue-qiong(Senior Department of Tuberculosis/Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment/Institute for Tuberculosis Research of the 8th Medical Center of Chinese PLA General Hospital,Beijing 100091,China)
出处
《中国防痨杂志》
CAS
CSCD
2022年第6期539-543,共5页
Chinese Journal of Antituberculosis
基金
医学创新工程专项重点项目(18CXZ028)。
关键词
结核
免疫疗法
总结性报告(主题)
评论
Tuberculosis
Immunotherapy
Consensus development conferences as topic
Comment
